ClinicalTrials.gg
CompletedNCT07030595RESPOND-1Updated Nov 17, 2025

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

A Phase 3 interventional study of AP301 and Sevelamer carbonate (Renvela®) in ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) and Hyperphosphatemia, sponsored by Alebund Pharmaceuticals. Completed at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Alebund Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jun 2023, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Enrollment
45th of 164
474 · median 182
Started
2023
with 22 others
Phase 3
39 of 245
12 open now
Registered
193rd of 245
by date

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 45th largest by enrollment of the 164 interventional ones that give a count, is one of 23 that started in 2023, is one of 39 in phase 3, and was the 193rd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese patients with hyperphosphatemia.

Read the detailed description

This study has two primary efficacy objectives. The primary efficacy objective 1 is to evaluate the superiority of maintenance dose versus low dose of AP301 on serum P control in dialysis patients with hyperphosphatemia. The primary efficacy objective 2 is to evaluate the non-inferiority of AP301 versus sevelamer carbonate on serum phosphorus control. Besides these two primary efficacy objectives, this study will also evaluate the serum phosphorus control equivalence and the safety for AP301 produced from two APIs (Active Pharmaceutical Ingredient) in the last 8 weeks of drug exposure.

Patients will start dosed after eligibility confirmation. The treatment period will last 52 weeks in total, including:

A) A 24-week sevelamer carbonate active control phase in which serum phosphorus level at the end of Week 12 will be measured for the analysis of primary efficacy endpoint 2, B) A 3-week AP301 low dose control phase in which serum phosphorus level at the end of Week 27 will be measured for the analysis of primary efficacy endpoint 1, and C) A 25 or 28-week extension treatment phase

The investigational treatments will be AP301. Sevelamer carbonate will be provided as active control in active control and extension treatment phase and AP301 125 mg as ineffective control in low dose control phase.

A) The starting dose of AP301 is one 700 mg capsule 3 times daily. The dosage is to be adjusted based on their serum phosphorus level and safety assessmentsevery two or four weeks. The maximal dose is to be 10 capsules daily.

B) The starting dose of sevelamer carbonate will be one to two 800 mg capsules 3 times daily. The dosage is to be adjusted based on their serum phosphorus level every and safety assessments two or four weeks. The maximal dose is to be 12 capsules daily.

Then, a 2-week safety observation will be followed after the last dosing.

03

Conditions studied

  • ESRD (End Stage Renal Disease)
  • Chronic Kidney Disease(CKD)
  • Hyperphosphatemia
  • Hyperphosphatemia in Chronic Kidney Disease
  • Dialysis
  • Chronic Kidney Disease, Receiving Dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Provision of signed and dated ICF
  • Adult when signing the ICF
  • Patients on dialysis for ≥ 3 months before signing the ICF and throughout the study
  • For HD patients, spKt/V ≥ 1.2; for PD patients, total Kt/V ≥ 1.7/week
  • For patients who receive phosphate binders and their serum phosphate level is:

    1. Screening: 1.13 mmol/L (3.5 mg/dL) ≤ serum phosphate \< 2.58 mmol/L (8.0 mg/dL)
    2. After washout: 1.94 mmol/L (6.0 mg/dL) ≤ serum phosphate \< 3.23 mmol/L (10.0 mg/dL)
  • For patients who do not receive phosphate binders over 2 weeks and their serum phosphate level is:

    1. Screening: 1.94 mmol/L (6.0 mg/dL) ≤ serum phosphate \< 3.23 mmol/L (10.0 mg/dL)

Key Exclusion Criteria:

  • History or plan of kidney transplantation
  • History or plan of parathyroid intervention 6 months before signing the ICF
  • Serum calcium \< 1.9 mmol/L (7.6 mg/dL) or > 2.75 mmol/L (11 mg/dL) at screening
  • Serum intact parathyroid hormone > 110 pmol/L (1000 pg/mL) at screening
  • Presence of gastrointestinal (GI) disorder
  • History of gastrectomy or duodenectomy, or GI surgery within 3 months before signing the ICF
  • Known allergic to any ingredient of AP301 or Sevelamer Carbonate, or known history of severe allergies leading to emergency medical care
  • Female who are breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
474 participants (actual)

Study arms

  • Experimental
    AP301

    A blood phosphate-lowering medication containing iron

    Drug: AP301

  • Active comparator
    Sevelamer Carbonate

    A marketed blood phosphate-lowering medication

    Drug: Sevelamer carbonate (Renvela®)

  • Experimental
    AP301 Low Dose

    A blood phosphate-lowering medication containing iron, but with a low dose considered as ineffective

    Drug: AP301 Low Dose

Interventions

  • DrugAP301

    Three times a day, administered orally with three meals at a daily dose level from 2.1g to 9.1g

  • Three times a day, administered orally with three meals at a daily dose level from 2.4g to 9.6g

  • Three times a day, administered orally with three meals at a daily dose level of 0.375g.

06

What researchers measure

Primary outcomes

  1. Change in serum phosphorus levels between AP301 and AP301 low dose groups in hyperphosphatemic patients

    The serum phosphorus will be measured with a standard laboratory test. The change in serum phosphorus levels will be compared between the group receiving AP301 and the group receiving AP301 low dose.

    Time frame: From the end of Week 24 to the end of Week 27

  2. Change in serum phosphorus levels between AP301 and sevelamer carbonate groups in hyperphosphatemic patients

    The serum phosphorus will be measured with a standard laboratory test. The change in serum phosphorus levels will be compared between the group receiving AP301 and the group receiving sevelamer carbonate.

    Time frame: From Baseline to the end of Week 12

Secondary outcomes

  1. The achievement rate of serum phosphorus in the target range 1.13-1.78 mmol/L (3.5-5.5 mg/dL) (both inclusive).

    The serum phosphorus will be measured with a standard laboratory test.

    Time frame: From Baseline to the end of Week 52.

  2. Changes in serum calcium

    The serum calcium in the blood will be measured with a standard laboratory test.

    Time frame: From Baseline to the end of Week 52

  3. Changes in serum calcium times phosphorus product

    The serum calcium and phosphorus in the blood will be measured with standard laboratory tests.

    Time frame: From Baseline to the end of Week 52

  4. Changes in intact parathyroid hormone

    The intact parathyroid hormone in the blood will be measured with a standard laboratory test.

    Time frame: From Baseline to the end of Week 52

  5. Changes in serum bone-specific alkaline phosphatase

    The serum bone-specific alkaline phosphatase in the blood will be measured with standard laboratory tests.

    Time frame: From Baseline to the end of Week 52

  6. Changes in osteocalcin

    The serum osteocalcin in the blood will be measured with a standard laboratory test.

    Time frame: From Baseline to the end of Week 52

  7. Number of adverse events

    Time frame: From Baseline to Follow-up (up to 54 weeks)

  8. Changes in serum iron parameters

    The serum iron parameters will be measured with standard laboratory tests.

    Time frame: From Baseline to the end of Week 52

  9. Change in QT intervals measured by 12-lead electrocardiogram test over time

    The duration of QT intervals will be measured with a standard 12-lead electrocardiogram test.

    Time frame: From Baseline to the end of Week 52

  10. Number of participants with abnormal vital signs

    The vital sign will consist of pulse rate and blood pressure with standard measurements.

    Time frame: From Baseline to the end of Week 52

  11. Number of participants with abnormal laboratory tests results

    The laboratory tests will be measured with standard validated methods, involving hematology, biochemistry, bone markers, iron parameters and others.

    Time frame: From Baseline to the end of Week 52

Other outcomes

  1. Changes in average serum phosphorus levels

    The serum phosphorus will be measured with a standard laboratory test.

    Time frame: From the end of Week 48 to the end of Week 52

  2. Number of adverse events

    Time frame: From the end of Week 48 to the end of Week 52

07

Study locations

50 sites
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing Municipality 100029, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Jishuitan Hospital
    Beijing, Beijing Municipality 100035, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100082, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Peking University International Hospital
    Beijing, Beijing Municipality 102206, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing Municipality 102218, China
  • Jilin Province People's Hospital
    Jilin City, Changchun 130021, China
  • The Second Norman Bethune Hospital of Jilin University
    Jilin City, Changchun 130041, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • Dongguan People's Hospital
    Guangzhou, Guangdong 523058, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
  • The First People's Hospital of Nanning
    Nanning, Guangxi 530016, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050052, China
  • The Second Affiliated Hospital Of Xingtai Medical College
    Xingtai, Hebei 054002, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Hospital of Universal Love
    Wuhan, Hubei 430030, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410031, China
  • Changzhou NO.2 People's Hospital
    Changzhou, Jiangsu 213004, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Jiangsu Province Hosipital
    Nanjing, Jiangsu 210029, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 226007, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221009, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225003, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
  • Dalian Municipal Central Hospital
    Dalian, Liaoning 116083, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality 200072, China
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200082, China
  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200092, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200127, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality 200233, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • Tianjin People's Hospital
    Tianjin, Tianjin Municipality 300121, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2024, 15 months.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 15 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 22, 2025
StartActual
Jun 12, 2023
Primary completionActual
Oct 2, 2024
CompletionActual
May 30, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07030595
Lead sponsor
Alebund Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jun 12, 2023
Primary completion
Oct 2, 2024
Completion
May 30, 2025
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP301 peptide

Start the discussion